 Kimberley Bruce
Concepts (195)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Microglia | 3 | 2024 | 198 | 1.600 |
Why?
| | Fatty Liver | 4 | 2018 | 209 | 1.190 |
Why?
| | Lipoprotein Lipase | 4 | 2022 | 54 | 1.030 |
Why?
| | Non-alcoholic Fatty Liver Disease | 3 | 2019 | 244 | 1.000 |
Why?
| | Prenatal Exposure Delayed Effects | 6 | 2019 | 453 | 0.970 |
Why?
| | Lipid Metabolism | 3 | 2022 | 441 | 0.910 |
Why?
| | Lipoproteins | 2 | 2023 | 159 | 0.860 |
Why?
| | Metabolic Syndrome | 3 | 2011 | 320 | 0.820 |
Why?
| | Fatty Acids | 2 | 2022 | 380 | 0.810 |
Why?
| | Brain | 3 | 2024 | 2355 | 0.810 |
Why?
| | Neuroglia | 1 | 2022 | 149 | 0.760 |
Why?
| | Optical Imaging | 1 | 2021 | 52 | 0.750 |
Why?
| | Lipid Droplets | 1 | 2021 | 21 | 0.730 |
Why?
| | DNA Methylation | 2 | 2023 | 493 | 0.730 |
Why?
| | Glucose Intolerance | 1 | 2022 | 137 | 0.720 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2022 | 373 | 0.710 |
Why?
| | Neurodegenerative Diseases | 1 | 2021 | 92 | 0.690 |
Why?
| | Circadian Clocks | 4 | 2019 | 42 | 0.660 |
Why?
| | Neurons | 3 | 2022 | 1277 | 0.650 |
Why?
| | Diet, High-Fat | 8 | 2019 | 225 | 0.630 |
Why?
| | Alzheimer Disease | 1 | 2024 | 442 | 0.620 |
Why?
| | Genes, Essential | 4 | 2014 | 18 | 0.550 |
Why?
| | CLOCK Proteins | 1 | 2016 | 8 | 0.530 |
Why?
| | Sirtuin 1 | 1 | 2016 | 29 | 0.520 |
Why?
| | Gastrointestinal Microbiome | 1 | 2022 | 502 | 0.510 |
Why?
| | Disease Susceptibility | 1 | 2018 | 316 | 0.510 |
Why?
| | Maternal Nutritional Physiological Phenomena | 4 | 2014 | 141 | 0.510 |
Why?
| | Sirtuin 3 | 1 | 2016 | 51 | 0.500 |
Why?
| | Disease Models, Animal | 5 | 2019 | 3498 | 0.490 |
Why?
| | Nutritional Physiological Phenomena | 2 | 2012 | 47 | 0.480 |
Why?
| | Dietary Fats | 3 | 2016 | 287 | 0.480 |
Why?
| | Animals | 20 | 2024 | 31565 | 0.410 |
Why?
| | 14-3-3 Proteins | 1 | 2012 | 13 | 0.400 |
Why?
| | Mice | 15 | 2024 | 14841 | 0.380 |
Why?
| | Liver | 3 | 2016 | 1633 | 0.360 |
Why?
| | Lipogenesis | 2 | 2009 | 56 | 0.350 |
Why?
| | Epigenesis, Genetic | 2 | 2011 | 517 | 0.340 |
Why?
| | Mitochondria, Liver | 1 | 2009 | 67 | 0.330 |
Why?
| | Pregnancy | 9 | 2019 | 5499 | 0.290 |
Why?
| | Suprachiasmatic Nucleus | 2 | 2019 | 12 | 0.290 |
Why?
| | Gene Expression Regulation | 5 | 2021 | 2321 | 0.280 |
Why?
| | Energy Metabolism | 1 | 2012 | 727 | 0.280 |
Why?
| | Triglycerides | 3 | 2023 | 467 | 0.260 |
Why?
| | Mice, Inbred C57BL | 8 | 2017 | 4680 | 0.240 |
Why?
| | Phenotype | 4 | 2021 | 2784 | 0.230 |
Why?
| | Circadian Rhythm | 3 | 2016 | 356 | 0.220 |
Why?
| | Diet | 3 | 2023 | 1080 | 0.210 |
Why?
| | Gene Expression Profiling | 4 | 2021 | 1519 | 0.210 |
Why?
| | Receptors, Immunologic | 1 | 2024 | 198 | 0.210 |
Why?
| | Lipodystrophy | 1 | 2022 | 16 | 0.210 |
Why?
| | Hypertriglyceridemia | 1 | 2022 | 34 | 0.200 |
Why?
| | Obesity | 4 | 2018 | 2505 | 0.200 |
Why?
| | Humans | 17 | 2024 | 114043 | 0.200 |
Why?
| | Tissue Adhesions | 2 | 2012 | 26 | 0.190 |
Why?
| | Membrane Glycoproteins | 1 | 2024 | 429 | 0.190 |
Why?
| | Estrogens | 1 | 2024 | 312 | 0.190 |
Why?
| | Inflammation | 4 | 2021 | 2464 | 0.190 |
Why?
| | Peroxisome Proliferator-Activated Receptors | 1 | 2021 | 14 | 0.180 |
Why?
| | Substrate Specificity | 1 | 2021 | 350 | 0.180 |
Why?
| | Cholesterol, LDL | 1 | 2022 | 307 | 0.180 |
Why?
| | Ultracentrifugation | 1 | 2020 | 46 | 0.180 |
Why?
| | Positron-Emission Tomography | 1 | 2021 | 260 | 0.170 |
Why?
| | Tobramycin | 1 | 2019 | 47 | 0.170 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 2021 | 474 | 0.160 |
Why?
| | Insulin Resistance | 2 | 2022 | 1072 | 0.160 |
Why?
| | Phospholipids | 1 | 2021 | 194 | 0.160 |
Why?
| | Exosomes | 1 | 2020 | 92 | 0.160 |
Why?
| | Hypothalamus | 2 | 2017 | 147 | 0.160 |
Why?
| | Cholesterol | 1 | 2021 | 368 | 0.160 |
Why?
| | Photoperiod | 2 | 2016 | 48 | 0.160 |
Why?
| | Female | 13 | 2024 | 59325 | 0.160 |
Why?
| | Quinolines | 1 | 2019 | 129 | 0.160 |
Why?
| | Precision Medicine | 1 | 2022 | 335 | 0.160 |
Why?
| | Cell Line | 2 | 2021 | 2629 | 0.150 |
Why?
| | Pseudomonas aeruginosa | 1 | 2019 | 298 | 0.140 |
Why?
| | Pravastatin | 1 | 2017 | 28 | 0.140 |
Why?
| | Nanoparticles | 1 | 2020 | 312 | 0.140 |
Why?
| | Simvastatin | 1 | 2017 | 58 | 0.140 |
Why?
| | Glucose | 2 | 2022 | 899 | 0.130 |
Why?
| | Fibrosis | 1 | 2019 | 452 | 0.130 |
Why?
| | Nuclear Receptor Subfamily 1, Group F, Member 1 | 1 | 2016 | 4 | 0.130 |
Why?
| | Nuclear Receptor Subfamily 1, Group D, Member 1 | 1 | 2016 | 3 | 0.130 |
Why?
| | Maternal Exposure | 1 | 2018 | 138 | 0.130 |
Why?
| | Muscular Diseases | 1 | 2017 | 104 | 0.130 |
Why?
| | Sterol Regulatory Element Binding Protein 1 | 1 | 2016 | 54 | 0.130 |
Why?
| | Hyperlipidemias | 1 | 2017 | 121 | 0.130 |
Why?
| | Acidosis | 1 | 2017 | 86 | 0.130 |
Why?
| | Body Composition | 2 | 2017 | 590 | 0.130 |
Why?
| | Oxidation-Reduction | 2 | 2016 | 917 | 0.120 |
Why?
| | Proteomics | 1 | 2020 | 815 | 0.120 |
Why?
| | Eating | 2 | 2019 | 344 | 0.120 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 1 | 2016 | 192 | 0.120 |
Why?
| | Glyceraldehyde-3-Phosphate Dehydrogenases | 1 | 2014 | 14 | 0.120 |
Why?
| | Mitochondrial Proton-Translocating ATPases | 1 | 2014 | 17 | 0.120 |
Why?
| | Biopsy | 1 | 2018 | 1024 | 0.110 |
Why?
| | Aging | 1 | 2024 | 1611 | 0.110 |
Why?
| | Adiposity | 2 | 2016 | 458 | 0.110 |
Why?
| | Weight Gain | 1 | 2017 | 453 | 0.110 |
Why?
| | Immunohistochemistry | 1 | 2018 | 1624 | 0.110 |
Why?
| | Repressor Proteins | 1 | 2016 | 367 | 0.110 |
Why?
| | Ovary | 1 | 2014 | 190 | 0.100 |
Why?
| | Prenatal Nutritional Physiological Phenomena | 2 | 2009 | 57 | 0.100 |
Why?
| | Appetite | 1 | 2012 | 52 | 0.100 |
Why?
| | Actins | 1 | 2014 | 376 | 0.100 |
Why?
| | Liver Transplantation | 1 | 2019 | 695 | 0.100 |
Why?
| | Disease Progression | 1 | 2019 | 2371 | 0.100 |
Why?
| | Endometrium | 1 | 2011 | 60 | 0.090 |
Why?
| | Epithelium | 1 | 2012 | 295 | 0.090 |
Why?
| | Models, Biological | 3 | 2017 | 1611 | 0.090 |
Why?
| | Blood Vessels | 1 | 2012 | 179 | 0.090 |
Why?
| | Magnetic Resonance Imaging | 1 | 2021 | 3039 | 0.090 |
Why?
| | Pelvic Pain | 1 | 2010 | 32 | 0.090 |
Why?
| | Hyaluronan Receptors | 1 | 2009 | 90 | 0.080 |
Why?
| | Adipokines | 1 | 2009 | 42 | 0.080 |
Why?
| | Electron Transport | 1 | 2009 | 108 | 0.080 |
Why?
| | Polycystic Ovary Syndrome | 1 | 2011 | 141 | 0.080 |
Why?
| | Intra-Abdominal Fat | 1 | 2009 | 77 | 0.080 |
Why?
| | Male | 8 | 2024 | 55396 | 0.080 |
Why?
| | Lactation | 1 | 2009 | 149 | 0.080 |
Why?
| | Genetic Variation | 1 | 2012 | 868 | 0.070 |
Why?
| | Feeding Behavior | 1 | 2012 | 572 | 0.070 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2012 | 801 | 0.070 |
Why?
| | Body Weight | 3 | 2017 | 868 | 0.070 |
Why?
| | Polymerase Chain Reaction | 1 | 2009 | 990 | 0.070 |
Why?
| | Oxidative Stress | 2 | 2009 | 1068 | 0.070 |
Why?
| | Histones | 1 | 2011 | 529 | 0.070 |
Why?
| | Aged | 1 | 2024 | 18969 | 0.060 |
Why?
| | Sleep | 1 | 2010 | 631 | 0.060 |
Why?
| | Middle Aged | 1 | 2024 | 26605 | 0.060 |
Why?
| | Gene Expression | 3 | 2014 | 1417 | 0.050 |
Why?
| | MicroRNAs | 1 | 2009 | 600 | 0.050 |
Why?
| | Signal Transduction | 1 | 2016 | 4501 | 0.050 |
Why?
| | Apolipoprotein C-III | 1 | 2022 | 13 | 0.050 |
Why?
| | Oligonucleotides, Antisense | 1 | 2022 | 100 | 0.050 |
Why?
| | Genetic Predisposition to Disease | 1 | 2010 | 2090 | 0.050 |
Why?
| | Abdomen | 2 | 2012 | 99 | 0.050 |
Why?
| | Chemical Precipitation | 1 | 2020 | 37 | 0.040 |
Why?
| | Benzofurans | 1 | 2019 | 18 | 0.040 |
Why?
| | Microbial Viability | 1 | 2019 | 79 | 0.040 |
Why?
| | Drug Synergism | 1 | 2019 | 315 | 0.040 |
Why?
| | Microbial Sensitivity Tests | 1 | 2019 | 300 | 0.040 |
Why?
| | Risk Factors | 1 | 2011 | 8614 | 0.040 |
Why?
| | Chylomicron Remnants | 1 | 2017 | 1 | 0.040 |
Why?
| | Calorimetry | 1 | 2017 | 60 | 0.030 |
Why?
| | Dependovirus | 1 | 2017 | 52 | 0.030 |
Why?
| | Mice, Knockout | 2 | 2016 | 2562 | 0.030 |
Why?
| | Hydrolysis | 1 | 2017 | 173 | 0.030 |
Why?
| | Ceramides | 1 | 2017 | 91 | 0.030 |
Why?
| | Calorimetry, Indirect | 1 | 2016 | 69 | 0.030 |
Why?
| | Glucose Tolerance Test | 1 | 2017 | 343 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2019 | 1836 | 0.030 |
Why?
| | Gene Deletion | 1 | 2017 | 356 | 0.030 |
Why?
| | Green Fluorescent Proteins | 1 | 2017 | 370 | 0.030 |
Why?
| | Adult | 4 | 2022 | 30375 | 0.030 |
Why?
| | Algorithms | 2 | 2012 | 1469 | 0.030 |
Why?
| | Time Factors | 2 | 2017 | 6077 | 0.030 |
Why?
| | Homeostasis | 1 | 2017 | 570 | 0.030 |
Why?
| | Lipids | 1 | 2017 | 564 | 0.030 |
Why?
| | Organ Size | 1 | 2014 | 434 | 0.030 |
Why?
| | Weaning | 1 | 2012 | 48 | 0.030 |
Why?
| | Peritoneum | 1 | 2012 | 36 | 0.030 |
Why?
| | Gynecologic Surgical Procedures | 1 | 2012 | 44 | 0.030 |
Why?
| | Systole | 1 | 2012 | 176 | 0.030 |
Why?
| | Animals, Newborn | 1 | 2014 | 777 | 0.020 |
Why?
| | Mice, Transgenic | 1 | 2017 | 1947 | 0.020 |
Why?
| | Nitric Oxide Synthase Type III | 1 | 2012 | 181 | 0.020 |
Why?
| | Reference Standards | 1 | 2012 | 159 | 0.020 |
Why?
| | DNA Topoisomerases, Type I | 1 | 2011 | 16 | 0.020 |
Why?
| | Femur | 1 | 2012 | 191 | 0.020 |
Why?
| | Vasoconstriction | 1 | 2012 | 177 | 0.020 |
Why?
| | Femoral Artery | 1 | 2012 | 165 | 0.020 |
Why?
| | Peritoneal Diseases | 1 | 2010 | 4 | 0.020 |
Why?
| | Menstrual Cycle | 1 | 2011 | 108 | 0.020 |
Why?
| | Plasminogen Activator Inhibitor 1 | 1 | 2010 | 75 | 0.020 |
Why?
| | Intestinal Obstruction | 1 | 2010 | 39 | 0.020 |
Why?
| | Preoperative Care | 1 | 2012 | 319 | 0.020 |
Why?
| | Analysis of Variance | 1 | 2012 | 1218 | 0.020 |
Why?
| | Vasodilation | 1 | 2012 | 418 | 0.020 |
Why?
| | Insulin-Like Growth Factor II | 1 | 2009 | 23 | 0.020 |
Why?
| | PPAR alpha | 1 | 2009 | 52 | 0.020 |
Why?
| | Microarray Analysis | 1 | 2009 | 118 | 0.020 |
Why?
| | Carnitine O-Palmitoyltransferase | 1 | 2009 | 43 | 0.020 |
Why?
| | Laparoscopy | 1 | 2012 | 395 | 0.020 |
Why?
| | Nitric Oxide | 1 | 2012 | 817 | 0.020 |
Why?
| | Software | 1 | 2011 | 527 | 0.020 |
Why?
| | Interleukin-6 | 1 | 2010 | 673 | 0.020 |
Why?
| | Up-Regulation | 1 | 2009 | 802 | 0.020 |
Why?
| | Blood Pressure | 1 | 2012 | 1531 | 0.020 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2010 | 1128 | 0.020 |
Why?
| | RNA | 1 | 2011 | 807 | 0.020 |
Why?
| | Chronic Disease | 1 | 2010 | 1577 | 0.010 |
Why?
| | Case-Control Studies | 1 | 2011 | 3003 | 0.010 |
Why?
| | RNA, Messenger | 1 | 2009 | 2550 | 0.010 |
Why?
| | Biomarkers | 1 | 2009 | 3397 | 0.010 |
Why?
| | Cardiovascular Diseases | 1 | 2009 | 1726 | 0.010 |
Why?
|
|
Bruce's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|